Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia

Howard A. Liebman; Mansoor N. Saleh; James B. Bussel; O. George Negrea; Heather Horne; William A. Wegener; David M. Goldenberg

doi:10.3324/haematol.2016.146738

Haematologica (Nov 2016)

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia

Howard A. Liebman,
Mansoor N. Saleh,
James B. Bussel,
O. George Negrea,
Heather Horne,
William A. Wegener,
David M. Goldenberg

Affiliations

Howard A. Liebman: Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
Mansoor N. Saleh: Georgia Cancer Specialists, Atlanta, GA, USA
James B. Bussel: Platelet Disorders Center, Division of Pediatric Hematology-Oncology, New York Presbyterian Hospital, NY, USA
O. George Negrea: Low Country Cancer Care Assoc., Savannah, GA, USA
Heather Horne: Immunomedics, Inc., Morris Plains, NJ, USA
William A. Wegener: Immunomedics, Inc., Morris Plains, NJ, USA
David M. Goldenberg: Immunomedics, Inc., Morris Plains, NJ, USA

DOI: https://doi.org/10.3324/haematol.2016.146738
Journal volume & issue: Vol. 101, no. 11

Abstract

Read online

We compared two dosing schedules for subcutaneous injections of a low-dose humanized anti-CD20 antibody, veltuzumab, in immune thrombocytopenia. Fifty adults with primary immune thrombocytopenia, in whom one or more lines of standard therapy had failed and who had a platelet count

Published in Haematologica

ISSN: 0390-6078 (Print); 1592-8721 (Online)
Publisher: Ferrata Storti Foundation
Country of publisher: Italy
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: http://www.haematologica.org

About the journal